title: Drug eluting stents may not be the answer for myocardial bridges.
abstract: Although medical treatment is the first-line therapy for myocardial bridges, in some cases revascularization may be required. Percutaneous intervention with bare metal stents is associated with a high restenosis rate. It has been speculated that drug eluting stents might be useful in this setting, although data are limited. We present a patient who suffered multifocal in-stent restenosis after a paclitaxel stent in a myocardial bridge.
authors.forename: Juan
authors.initials: J
authors.lastname: Rondan
authors.forename: Inigo
authors.initials: I
authors.lastname: Lozano
authors.forename: Pablo
authors.initials: P
authors.lastname: Avanzas
authors.forename: Ramon
authors.initials: R
authors.lastname: Lopez-Palop
authors.forename: Jose M
authors.initials: JM
authors.lastname: Vegas
authors.forename: Cesar
authors.initials: C
authors.lastname: Moris
mesh_terms: D000789:Angina, Unstable / Q000628:therapy; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D023903:Coronary Restenosis / Q000209:etiology*; D003330:Coronary Vessel Anomalies / Q000628:therapy*; D016503:Drug Delivery Systems; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects*; D015607:Stents / Q000009:adverse effects*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel